Synopsis: Achyut Healthcare Limited’s board has approved a scheme of amalgamation with Zenith Healthcare Limited, under which Achyut will merge into Zenith and subsequently be dissolved without winding up. Achyut shareholders will receive 119 equity shares of Zenith Healthcare for every 50 shares held in Achyut Healthcare, subject to regulatory, NCLT, shareholder and creditor approvals.
Shares of Achyut Healthcare Limited are likely to remain in focus after the company’s Board of Directors approved a scheme of amalgamation with Zenith Healthcare Limited, a pharmaceutical manufacturing, marketing and export company belonging to the same promoter group.
Achyut Healthcare Limited has a total market capitalization of approximately Rs. 181 crore. The company’s shares were trading at Rs. 7.98 apiece on the stock exchange, up by 1.27 percent. The stock has declined 4.43 percent over the last five trading sessions, while it has gained 21.28 percent over the last month. The stock touched a 52-week high of Rs. 10.04 and a 52-week low of Rs. 3.65.
According to the company’s exchange filing, the Board of Achyut Healthcare approved the amalgamation on July 14, 2026, after considering recommendations from its Audit Committee and Committee of Independent Directors. Under the proposed scheme, Achyut Healthcare will be the transferor company and will merge with and into Zenith Healthcare, the transferee company. Following the scheme becoming effective, Achyut Healthcare will be dissolved without winding up and its existing shares will stand cancelled.
Under the approved share exchange ratio, shareholders of Achyut Healthcare will receive 119 fully paid-up equity shares of Zenith Healthcare with a face value of Rs. 1 each for every 50 fully paid-up equity shares of Achyut Healthcare held. No cash consideration will be paid under the scheme. The exchange ratio has been determined based on independent valuation reports, while a SEBI-registered merchant banker has issued a fairness opinion on the proposed ratio.
The proposed amalgamation remains subject to several approvals, including from the appropriate statutory and regulatory authorities, the jurisdictional bench of the National Company Law Tribunal, and the shareholders and creditors of the companies. Achyut Healthcare will also file the scheme with BSE for the required no-objection or observation letter.
The merger brings together two companies operating in similar and complementary pharmaceutical businesses. Achyut Healthcare is engaged in trading active pharmaceutical ingredients and pharmaceutical products and is also developing a new manufacturing facility in Ahmedabad. Zenith Healthcare, meanwhile, manufactures, markets, sells and exports pharmaceutical and medical products.
Achyut Healthcare’s upcoming manufacturing facility is being developed for the production of general tablets, effervescent tablets, general and soft-gel capsules, liquid inhalation products including Sevoflurane and sachets. The facility is intended to meet internationally recognised manufacturing standards, including GMP, WHO cGMP and EU certification requirements, subject to the necessary approvals and certifications.
Zenith Healthcare already manufactures products including human tablets and capsules, oral liquids, dry powders, directly compressible granules and specialised psychotropic and narcotic products. Its existing manufacturing facility conforms to WHO cGMP standards, and the company exports its products to 11 countries. The merger could therefore combine Zenith’s existing manufacturing and export network with Achyut’s planned production capacity and specialised product portfolio.
The proposed amalgamation is expected to improve manufacturing capacity utilisation, broaden the combined product portfolio and strengthen marketing and distribution capabilities. It could also create economies of scale across procurement, manufacturing, distribution and trading while reducing duplicated administrative and compliance costs. A larger combined balance sheet may additionally improve financial flexibility and support future expansion.
The two companies reported a combined FY26 turnover, including other income, of approximately Rs. 22.91 crore. Achyut Healthcare reported turnover of Rs. 11.97 crore, total assets of Rs. 38.09 crore and net worth of Rs. 35.06 crore as of March 31, 2026. Zenith Healthcare reported turnover of Rs. 10.94 crore, total assets of Rs. 10.99 crore and net worth of Rs. 7.42 crore.
For investors, the proposed merger represents a significant structural change for Achyut Healthcare. Shareholders will transition from owning shares in Achyut to holding shares in the combined Zenith Healthcare entity based on the 119:50 exchange ratio. The potential benefits include access to a broader pharmaceutical portfolio, manufacturing synergies, an established export presence and the planned addition of new production capabilities. However, completion of the transaction remains dependent on multiple regulatory and stakeholder approvals.
Incorporated in 1996, Achyut Healthcare Limited is a pharmaceutical trading company engaged in dealing in active pharmaceutical ingredients, pharmaceutical products and related healthcare products. The company is also developing manufacturing capabilities for multiple pharmaceutical dosage forms, which are expected to complement Zenith Healthcare’s existing manufacturing and export operations following the proposed amalgamation.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses arising from decisions based on this article. Please consult your investment advisor before investing.
